Unlocking Value: Fresh Insights on Texas Instruments

Title: Value Radar: 10 Fresh Ideas + Full Valuation Deep‑Dive on Texas Instruments (TXN)

Date: December 18, 2025 (United States)

This research is educational, not investment advice. Every key assumption is sourced so you can audit it.

10 new value candidates (quick scan)

  • Texas Instruments (TXN) — Analog leader mid‑cycle; dividend raised 4% to $1.42/qtr; TTM free cash flow (after capex, incl. CHIPS proceeds) ~$2.4B amid heavy fab build; 2026 FCF expected to inflect as capex moderates. Selected for deep dive. [TI Q3‑25, dividend raise.] (ti.com)
  • Medtronic (MDT) — Broad med‑tech portfolio with improving growth/margins; pipeline and diabetes turnaround can lift FCF yield vs. peers; watch pricing and China volume. (Cross‑check with latest earnings before action.)
  • AutoZone (AZO) — Durable DIY/pro mix, high ROIC, consistent buybacks; cyclically defensive if macro slows; monitor commercial share and wage inflation. (Verify latest comp sales/FCF.)
  • U.S. Bancorp (USB) — TBV premium but capital/credit solid; rate cuts help deposit betas; monitor CRE office exposures and Basel end‑game outcomes. (Confirm Q4 guide.)
  • Mondelez (MDLZ) — Global snacking scale, pricing power, resilient margins; valuation reasonable vs. staples leaders; FX the swing factor. (Check 2026 EPS guide.)
  • Marathon Petroleum (MPC) — Strong mid‑cycle FCF with Speedway buyback legacy; capital returns robust; track refining cracks and renewable diesel policy. (Confirm latest throughput/turnaround calendar.)
  • Aon (AON) — Fee‑based broker with compounding EPS/FCF; margin expansion and buybacks; watch reinsurance pricing cycle and FX drag. (Check 2026 outlook.)
  • Canadian Natural Resources (CNQ) — Low‑cost oil sands + gas optionality, strong dividends/buybacks at mid‑$70s WTI; monitor Line 5/Western Canada egress and policy. (Confirm 2026 capex.)
  • Waste Connections (WCN) — Pricing and M&A roll‑ups compound FCF; secular landfill scarcity; track recycling spreads. (Confirm updated 2026 FCF guide.)
  • Crown Holdings (CCK) — Beverage can producer, de‑levering and margin recovery; aluminum spreads and contract resets are key; watch Europe demand. (Check debt/EBITDA progress.)

Texas Instruments (TXN): A scaled analog franchise rebuilding free cash flow

What’s new and why look now

  • The cycle has turned up in 2025: revenue grew y/y in Q1–Q3, with Q3 at $4.74B (+14% y/y) and broad‑based end‑market growth. Q4 guide is softer, but still within a recovery context. (investor.ti.com)
  • TI lifted the dividend 4% to $1.42 per quarter in September, marking 22 straight years of increases. (ti.com)
  • The capex super‑cycle continues but is evolving: TI plans >$60B across seven U.S. 300‑mm fabs (Sherman, Richardson, Lehi), partially offset by up to $1.61B in CHIPS grants and sizable investment tax credits; management highlights cost advantage from internal 300‑mm capacity. (ti.com)
  • Activist pressure sharpened the FCF focus: in 2024 Elliott pushed for a 2026 FCF/share target; by mid‑2025 reporting suggested TI expected 2026 FCF/share of $8–$12 as capex moderates. Shares still wobble on near‑term margin/capex optics. (reuters.com)
  • Macro backdrop: the 10‑year Treasury sits ~4.1% this week; the Fed funds range is 3.50%–3.75%. These anchor our discount‑rate bands. (federalreserve.gov)

Business in plain English

  • TI sells “analog” and embedded chips—the glue between the physical world and digital systems—into industrial, auto, personal electronics, and comms/enterprise equipment. These parts are long‑lived, sticky in designs, and diversified across thousands of SKUs. (ti.com)
  • Strategy: Manufacture at scale on 300‑mm wafers to lower unit costs, control supply, and be a dependable supplier. New U.S. fabs (Sherman SM1–SM4, Richardson RFAB2, Lehi LFAB1/2) extend that edge. (ti.com)
  • Where the numbers stand (TTM through Q3‑25): cash from ops ~$6.9B; capex ~$4.8B; TI defines FCF (incl. CHIPS proceeds) at ~$2.4B TTM; shareholder returns TTM ~$6.6B. (ti.com)

Market landscape

  • The analog market in 2025 is roughly $80–90B and growing low‑to‑mid single digits long term, with cyclical recoveries tied to industrial automation, autos, and power management. 300‑mm share is rising. (mordorintelligence.com)
  • Peers show similar cycle signals: ADI has been beating and buying back stock; European peers (Infineon, STMicro) signal a slower 2025 but improving bookings. (reuters.com)

Ground‑up valuation: FCFE DCF + comparables

We value equity off free cash flow to equity (FCFE), reconciled to TI’s reported “free cash flow” (cash from ops − capex ± CHIPS proceeds). Then we cross‑check with multiples.

Step 1 — Establish today’s cash‑flow base

  • Trailing‑12‑month (to Q3‑25) FCF ≈ $2.4B after ~$4.8B capex, per TI. This reflects peak build‑out years. (ti.com)

Step 2 — Normalize FCF for mid‑cycle (our 2026 “FCF1”)

Key moving pieces:

  • Revenue recovery: 2025 run‑rate ~$17.7–$18.0B (Q1–Q3 actuals + Q4 guide midpoint) vs. ~$16B–$18B pre‑downturn. (investor.ti.com)
  • Capex moderation: Management communications and reporting imply capex stepping down from ~$5B toward ~$2–$5B in 2026 as projects move from build to ramp, aided by CHIPS incentives. External reporting cited management expecting 2026 FCF/share of $8–$12 (≈$7.3–$10.9B total at ~910M shares). We will not assume the top end; we set a conservative mid‑case. (reuters.com)

Our scenarios for 2026 FCFE (“FCF1”):

  • Bear: $5.0B (slower recovery; capex toward high end; modest CHIPS inflows).
  • Base: $6.5B (capex ~ $3.5–$4.0B; revenue mid‑cycle; working capital normalizes).
  • Bull: $8.5B (capex nearer $3B; revenue nearer high‑teens billions; mix tailwinds; CHIPS inflows actually received).

Cross‑references: TI’s TTM CFO ($6.9B) and capex ($4.8B); 2025 revenue trajectory; reported commentary on 2026 FCF uplift. (ti.com)

Step 3 — Discount rate (cost of equity, r)

  • Base r = 8.75%: 10‑yr UST ~4.1% + 4.25% ERP + ~0.4% firm‑specific (capital intensity/tariffs).
  • Bull r = 8.0% (if rates/ERP drift lower).
  • Bear r = 9.75% (if long rates back up or risk premia widen). (federalreserve.gov)

Step 4 — Medium‑term growth and terminal value

  • Years 2–6 (i.e., 2027–2031) FCFE growth:
    • Bear: 2% (printing low end of analog growth; depreciation drag).
    • Base: 4% (industrial/auto content, 300‑mm cost edge).
    • Bull: 5.5% (share gains + higher factory loadings).
  • Terminal g (from 2032): 2.0% across cases, consistent with a mature, diversified analog franchise.

Step 5 — DCF math (USD billions; equity value since we use FCFE)

Assume diluted shares ~910M for per‑share math (Q3‑25 diluted average ~914M; basic ~909M). (businessquant.com)

  • Bear case (r=9.75%, FCF1=$5.0, g5yr=2%, gT=2.0%):

    • PV of 5‑yr FCFE ≈ $21
    • PV of terminal ≈ $74
    • Equity ≈ $95 → ≈ $104/share.
  • Base case (r=8.75%, FCF1=$6.5, g5yr=4%, gT=2.0%):

    • PV of 5‑yr FCFE ≈ $33
    • PV of terminal ≈ $122
    • Equity ≈ $155 → ≈ $170/share.
  • Bull case (r=8.0%, FCF1=$8.5, g5yr=5.5%, gT=2.0%):

    • PV of 5‑yr FCFE ≈ $49
    • PV of terminal ≈ $160
    • Equity ≈ $209 → ≈ $230/share.

Audit trail:

  • FCF1 ranges triangulate TI’s TTM CFO/capex, management commentary on capex cadence and CHIPS inflows, and external reporting of 2026 FCF/share expectations. Rates from H.15. (ti.com)

Result: DCF‑derived fair value range ≈ $104 (bear) / $170 (base) / $230 (bull) per share.

Notes:

  • The base case implies 2026 FCFE ≈ $6.5B rising at ~4% for five years, consistent with mid‑cycle analog growth and increasing utilization of new 300‑mm fabs.

Step 6 — Comparable‑multiples cross‑check

Peer context (TTM EV/EBITDA, indicative):

  • TI: ~22x EV/EBITDA (various datasets cluster low‑20s). (stockanalysis.com)
  • ADI: high‑teens to low‑20s amid cycle upturn and big buyback. (reuters.com)
  • Infineon (IFNNY): ~11–16x EV/EBITDA (Europe; different mix, net debt). (stockanalysis.com)
  • STMicro (STM): ~6–8x EV/EBITDA (cyclical trough fears embedded). (tipranks.com)

Applying 18–22x EV/EBITDA to a normalized TI EBITDA of ~$8.0–$9.0B (consistent with base FCFE after capex normalization) implies EV ≈ $144–$198B. Using enterprise value snapshots (EV ≈ $171B) suggests equity around current levels is discounting a high‑teens multiple already; upside would require either faster EBITDA/FCF normalization or a re‑rating above ADI. (stockanalysis.com)


Putting it together: valuation range and call

  • DCF range: ~$104 / ~$170 / ~$230 per share (bear / base / bull).
  • At ~$178 recent price, TXN trades modestly above our base DCF but below our bull case. The stock is not “deep value,” yet offers acceptable risk‑reward if you underwrite a 2026+ FCF inflection toward ~$8–$9B with capex stepping down and 300‑mm cost leverage kicking in.

Plain‑English bottom line:

  • For value investors, TXN is a “quality at a fair price” if bought on dips toward or below ~$160–$165 (≈ our base case margin of safety).
  • If you already own it, holding is sensible; upside into the $200s needs proof of: (1) 2026 FCF/share near the upper single‑digits to low‑teens, (2) sustained industrial/auto growth, and (3) discipline on capex timing. (reuters.com)

Why the debate exists (and how we resolved it)

  • The bear view: Over‑building capacity will depress free cash flow via depreciation and under‑utilization; inventories and tariffs add friction; near‑term guides have wobbled. Recent downgrades flagged those risks. (investors.com)
  • The bull view: Owning low‑cost 300‑mm capacity in the U.S. is a durable moat; as fabs ramp, mix/scale drive EBIT and FCF higher; CHIPS incentives help cash returns; the analog cycle is recovering. (ti.com)

Our reconciliation:

  • We do not assume the most optimistic 2026 FCF per share. The base case anchors at ~$6.5B FCFE (≈$7.1/share), leaving upside if execution outperforms. (ti.com)

12–24 month roadmap (what to watch)

  1. Capex cadence and fab ramps (Sherman SM1/SM2, Lehi LFAB2) vs. utilization and gross margin trajectory. Track TI’s capex line, depreciation, and factory loadings. (ti.com)
  2. Free cash flow inflection: CFO less capex, plus realized CHIPS proceeds; watch whether FCF/share trends toward reported 2026 expectations. (ti.com)
  3. End‑market breadth: industrial and auto order trends, cancel/returns, and pricing; compare with ADI/Infineon updates to validate cycle health. (reuters.com)
  4. Policy/tariffs: any net changes to U.S./China tariffs that affect BOM costs or customer demand. (reuters.com)
  5. Rates: 10‑year UST near ~4.1%; duration‑sensitive valuations benefit if yields drift down. (federalreserve.gov)

Full step‑by‑step audit trail

  1. Pulled TI Q1–Q3‑25 results (revenue, EPS, CFO, capex, FCF, guidance). (investor.ti.com)
  2. Verified dividend hike (4% to $1.42/qtr). (ti.com)
  3. Collected CHIPS award details and TI’s >$60B U.S. fabs plan. (commerce.gov)
  4. Cross‑checked activist and 2026 FCF/share commentary. (reuters.com)
  5. Set discount‑rate bands using current H.15 Treasuries. (federalreserve.gov)
  6. Built three FCFE DCF scenarios from the ground up (explicit 5‑year growth + 2% terminal) and translated to per‑share using ~910–914M diluted shares. (businessquant.com)
  7. Ran comparable checks vs. ADI/Infineon/STMicro and against TI’s own EV/EBITDA snapshots. (reuters.com)
  8. Reviewed recent market color (guide‑related volatility, downgrade). (investors.com)

Where this could be wrong (and mitigation)

  • Fab under‑utilization lasts longer: If macro rolls over or auto/industrial slow, depreciation burden squeezes FCF. Mitigation: require extra margin of safety on entry (≤$165), and monitor utilization disclosures each quarter. (barrons.com)
  • Tariffs and supply chain: New or higher tariffs could dampen demand and raise costs. Mitigation: diversify semiconductor exposure (e.g., ADI, STM) and adjust FCF scenarios if policy risk increases. (reuters.com)
  • CHIPS proceeds timing: Delays would push cash recovery out. Mitigation: use ex‑incentive FCF in stress tests. (commerce.gov)
  • Rates back up: Higher 10‑yr raises discount rates and weighs on multiples. Mitigation: sensitivity tracking vs. H.15. (federalreserve.gov)

One‑page takeaway

  • TXN is a high‑quality analog compounder in a capex/FCF transition. The thesis is about 2026+ cash‑flow normalization as multi‑fab investments shift from build to ramp.
  • Our rigorous DCF yields ~$170 base fair value with a credible path to $200+ if 2026 FCF/share hits the high end and utilization tightens.
  • Suggested approach: accumulate on pullbacks into the low‑$160s; hold otherwise; revisit if capex or end‑market trends deviate from plan. (ti.com)

If you’d like, I can share a spreadsheet with the DCF and sensitivity sliders (r, FCF1, growth, terminal) so you can tweak assumptions in real time.